The evidence session should allow the Committee to explore:
- the academic understanding of commercialising research and addressing the Valley of Death, thus establishing the base themes and provide context for the rest of the inquiry and
- the way in which bioscience has been commercialised, what is changing and whether there are lessons to be learned by other sectors.
Wednesday 18 April 2012
9.15 am in the Thatcher Room, Portcullis House
At 9.15 a.m.
- Professor Luke Georghiou, Vice-President (Research and Innovation), University of Manchester
- Dr Paul Nightingale, Science and Technology Policy Research, University of Sussex
- David Connell, Senior Research Fellow, Centre for Business Research/ UK Innovation Research Centre, Judge Business School, University of Cambridge
- Dr Douglas Robertson, Chair, Praxis-Unico
At 10.15 a.m
- Dr. Ted Bianco, Director of Technology Transfer, Wellcome Trust
- Dr. Ian Tomlinson, Senior Vice President, Head of Worldwide Business Development and Biopharmaceuticals R&D, GlaxoSmithKline
- Dr. David Tapolczay, Chief Executive Officer, Medical Research Council Technology
- Dr. Gareth Goodier, Chair, Shelford Group (Chief Executives of ten leading Academic Medical Centres and large teaching hospitals); Chief Executive, Cambridge University Hospitals NHS Foundation Trust
- Dr. Andy Richards, Serial biotechnology entrepreneur and business angel